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The combination of intravenous (i.v.) vinorelbine and epirubicin is highly active in the treatment of metastatic breast cancer (MBC). In
an effort to improve patient convenience, we investigated a regimen alternating i.v. and oral vinorelbine in combination with
epirubicin as first-line chemotherapy of patients with MBC. In all, 49 patients with MBC received, as first-line treatment, a combination
regimen consisting of i.v. vinorelbine 25mgm
 2 plus epirubicin 90mgm
 2 given on day 1, and oral vinorelbine 60mgm
 2 on day 8
(or day 15 if neutrophils o1500mm
 3) every 3 weeks, in an open-label, multicentre phase II study. Treatment was to be repeated
for a maximum of six cycles. The study population had a median age of 55 years, half of the patients had received prior adjuvant
chemotherapy and 86% presented a visceral involvement. In all, 25 responses were documented and validated by an independent
panel review, yielding response rates of 51% (95% CI: 36–66) in the 49 enrolled patients and 54.5% (95% CI: 39–70) in the 44
evaluable patients. Median durations of progression-free survival and survival were 8 and 20 months, respectively. Neutropenia was
the main dose-limiting toxicity, but complications were uncommon, four patients having experienced febrile neutropenia and six
having developed neutropenic infection. Other frequently reported adverse events included stomatitis, nausea and vomiting, which
were rarely severe. No toxic death was reported. Among patients who received six cycles, global score of quality of life remained
stable. This regimen alternating oral and i.v. vinorelbine in combination with epirubicin is effective and safe. Oral vinorelbine on day 8
offers greater convenience to the patient, and decreases the need for i.v. injection and reduces time spent in hospital. Therefore, oral
vinorelbine is a convenient alternative to the i.v. form in combination regimens commonly used to treat MBC.
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Breast cancer is the most common malignancy affecting women
in the Western world. Over the past decade, the lifetime risk of
developing breast cancer has been 12.2%. In Europe, the yearly
incidence is approximately 80 cases per 100000 women and
approximately half of them will die of the disease. Therapy for
metastatic breast cancer (MBC) has not improved significantly in
recent years, remaining strictly palliative in nature and intent.
While selected patients with advanced disease may have their
survival prolonged by combination chemotherapy, no patients
are cured. In this palliative setting, introduction of new regimens
that can improve patient comfort and convenience is highly
desirable.
Intravenous (i.v.) vinorelbine has been widely investigated in the
treatment of MBC. Response rates of 35–50% have consistently
been demonstrated for first-line single-agent vinorelbine
(Fumoleau et al, 1993; Garcia-Conde et al, 1994; Romero et al, 1994;
Twelves et al, 1994; Bruno et al, 1995; Weber et al, 1995; Terenziani
et al, 1996). The good tolerance profile of i.v. vinorelbine has
enabled its use in combination with other cytotoxic agents active
against MBC. It has been safely and effectively combined with
epirubicin in several noncomparative studies (Chadjaa et al, 1993;
Ezzat et al, 1996; Baldini et al, 1998; Tabiadon et al, 1998; Nistico
et al 1999; Vici et al, 2002). Recently, B Ejlertsen reported the
results of a randomised phase III study comparing the combina-
tion of i.v. vinorelbine 25mgm
 2 on days 1 and 8 and epirubicin
90mgm
 2 on day 1 with single-agent epirubicin 90mgm
 2 on day
1, both regimens being given every 3 weeks (Ejlertsen et al, 2001).
The combination of i.v. vinorelbine and epirubicin demonstrated a
trend for higher rate of objective responses (50 vs 42%) and
significantly longer duration of progression-free survival (10.1 vs
8.2 months). Leucopenia-related complications, stomatitis and
peripheral neuropathy were more common for the combination
regimen, but the incidences of cardiotoxicity, constipation and
injection site reactions were similar in the two study arms. This
phase III study established that addition of vinorelbine conferred a Revised 22 February 2005; accepted 23 March 2005
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ssignificant advantage over epirubicin used as a single agent in the
first-line treatment of MBC.
Oncology is one of the few areas of medicine where most
patients are treated i.v. rather than receiving oral drugs. Work
from Liu and colleagues (Liu et al, 1997) has indicated that
approximately 90% of cancer patients expressed a preference for
oral vs i.v. chemotherapy, predominantly because of the con-
venience of administration outside a hospital setting or current
concerns or previous problems with i.v. access. From a patient
perspective, the availability of oral agents would make a significant
contribution to patient’s quality of life, provided that the efficacy
and toxicity of these agents were comparable to that of their i.v.
counterparts. Oral vinorelbine belongs to the new generation of
oral drugs that achieve reliable blood exposure. Its bioavailability
is about 40%, which indicates that 80mgm
 2 orally corresponds to
30mgm
 2 i.v. and 60mgm
 2 orally to 25mgm
 2 i.v. (Marty et al,
2001). Used as a single agent for the first-line treatment of MBC
patients, oral vinorelbine was shown to be an effective and well-
tolerated agent (Freyer et al, 2003; Trillet-Lenoir et al, 2004).
In two phase II studies, consistent response rates of 30% were
reported. Also, median durations of progression-free survival and
survival fall in the same range: 4.2 and 24 months in one trial and
4.6 and 21 months in the other trial. Similarly to i.v. vinorelbine,
neutropenia was the main dose-limiting toxicity, but was rarely
complicated: only 4% of patients enrolled in the two phase II
studies experienced febrile neutropenia. No severe infection was
reported. Nausea and vomiting were more frequently reported with
oral vinorelbine in contrast to the usually low incidence seen with
the i.v. form. However, they were generally of mild-to-moderate
intensity. In subsequent studies of oral vinorelbine, a primary
prophylaxis with oral 5-HT3 antagonist was used and was shown
to easily control the occurrence of nausea and vomiting (Gridelli
et al, 2003).
Oral vinorelbine is, therefore, a useful alternative to the i.v. form
and deserves further clinical investigations in combination regi-
mens. The present study was designed to evaluate vinorelbine,
alternating i.v. on day 1 and oral on day 8, in combination with
epirubicin infused on day 1 every 3 weeks in patients with MBC.
MATERIALS AND METHODS
Eligibility
Eligible patients fulfilled all the following criteria: progressive
metastatic breast cancer; female aged X18 and p75 years;
Karnofsky performance status X70%; estimated life expectancy
X12 weeks; and who had adequate bone marrow, hepatic and
renal functions (defined as neutrophils X2.0 10
9l
 1, platelets
X100 10
9l
 1, haemoglobin X10gdl
 1 or 6.2mmoll
 1, total
bilirubin p1.5 upper limit of normal (ULN), AST and ALT
p2.5 ULN, creatinine p1.5 ULN). Patients were required to
have at least one bidimensionally measurable target lesion
(documented by CT or MRI according to WHO criteria), measured
within 21 days of inclusion in the study; physical examination,
ultrasound and chest X-ray were not considered as objective
tumour assessments. Prior therapy was permitted as follows: a
minimum of 2 weeks had to have elapsed between surgery and
inclusion in the study; patients might have had previous hormonal
therapy as adjuvant treatment and/or treatment of metastatic
disease provided that they had progressive disease at study entry;
previous neoadjuvant and/or adjuvant chemotherapy that might
have contained an anthracycline was allowed provided that an
interval of at least 12 months had elapsed between the end of
adjuvant chemotherapy and disease progression (for prior
adjuvant anthracycline/anthracenedione containing regimen, a
maximum prior dose of 180mgm
 2, 360mgm
 2 and 72mgm
 2
of doxorubicin, epirubicin or THP-adriamycin, and mitoxantrone
was allowed, respectively). No delay between the end of adjuvant
nonanthracycline/anthracenedione chemotherapy and study entry
was required provided that the patient had fully recovered from
toxic effects of prior adjuvant chemotherapy. Previous radiation
therapy may have been given provided that 4 weeks had elapsed
prior to study entry. However, the measurable disease had to be
completely outside the radiation field.
Cardiac function should be normal as demonstrated by LVEF
measured by radionuclide angiography (MUGA scan) or bidimen-
sional echocardiography performed within 3 weeks to study entry.
The protocol was submitted to independent ethics committees.
Their approvals were to be obtained prior to the start of the study.
The study was conducted in accordance with the ethical principles
set forth in the Declaration of Helsinki (Somerset West amend-
ment) and in compliance with all applicable local regulations.
Written informed consent was obtained from each participating
patient prior to entry into the study.
Treatment plan
The combination regimen consisted of i.v. vinorelbine 25mgm
 2
plus epirubicin 90mgm
 2 given on day 1, and oral vinorelbine
60mgm
 2 on day 8, every 3 weeks. Each patient received the study
drugs for a maximum of six cycles unless disease progression or
unacceptable toxicity. Treatment could be modified in the case of
haematological or nonhaematological toxicity, but the duration of
one cycle had not to exceed 5 weeks. Day 8 administration of oral
vinorelbine could be delayed by only 1 week; if oral dosing could
not be carried out on day 15, it had to be omitted.
In all centres involved in this clinical trial, the patient received
the study treatment at the hospital. Dose delay and/or cancellation
were depending on complete blood count results obtained within
24h and checked by the physician prior to dosing.
Treatment evaluation
Evaluation at study entry included physical examination, chest-ray
completed by chest CT scan if lung metastases, liver ultrasound
completed by abdominal CT scan if liver metastases and bone
scintigraphy. All positive imaging procedures had to be repeated
every two cycles and at the end of treatment. Thereafter, patients
were followed every 3 months until death. WHO criteria were
used to define response. Response rate was the primary
efficacy variable. All registered patients were included in the
efficacy analysis (intent-to-treat analysis). Patients evaluable
for efficacy were defined as those who remained in the study until
completion of the first evaluation (after first two cycles) as
required by protocol and whose baseline lesions were all assessed
with the same method of measurement throughout the study
period. All responses were validated by an independent radiologist.
Progression-free survival was calculated from the registration
date until the date of progression or death due to any cause.
Survival was defined as the time elapsed from registration date
until death or last contact.
Toxicity was evaluated by using the National Cancer Institute
criteria (version 2.0). Cardiac monitoring during the study
treatment included ECG before each cycle and assessment of
LVEF, if clinically indicated.
Quality of life was evaluated by using the EORTC QLQ-C30 and
QLQ-BR23 questionnaires.
Statistical analysis
The primary study objective was to assess the response rate.
Secondary objectives included safety evaluation, impact on quality
of life and determination of the duration of response, progression-
free survival and survival.
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phase II trial. The one-sample multiple testing procedure of
Fleming for phase II clinical trials was used. A minimum of 20
evaluable patients and a maximum of 40 evaluable patients
depending on the response rate observed in the first 20 subjects
were required. The procedure employed the standard single-stage
test procedure at the last one of k prespecified testing, while both
allowing for early termination (should extreme results be seen) and
essentially preserving the size and power of the single-stage
procedure. The reference responses rates, acceptable error
probabilities and number of testings selected for this study were
as follows: Po¼40%, Pa¼60%, a¼5%, b¼10%, k¼2. This
assumed that 40% was the minimum desirable response rate for an
active combination therapy in this population. Under these
conditions, the total sample size (N) was 40 evaluable patients
and the first test was performed after 20 evaluable patients.
RESULTS
Patients characteristics
In all, 49 patients with MBC were included in the study between
October 2000 and March 2002.
Patient and tumour characteristics are shown in Table 1. The
study population was rather young with a median age of 55 years.
A total of 28 patients (57%) had received prior adjuvant
chemotherapy, which contained anthracycline or anthracenedione
in 16 patients (57%). The majority presented visceral lesions,
which involved the liver (51% of the patients) or the lung (37%).
Treatment delivery
A total of 259 cycles were administered. The median number of
cycles was 6 with a range 1–7. Of note, 82% of the patients remain
under treatment until the fifth cycle and 74% complete the sixth
cycle. Excessive toxicity and disease progression were responsible
for the study discontinuation of four patients (8%) each. Other
reasons included patient’s refusal, investigator’s decision for two
patients (4%) each and nontoxic death for one patient.
Only few administrations were delayed, leading to high median
relative dose intensities. Among the 49 treated patients, the median
relative dose intensities for i.v. and oral vinorelbine were 95 and
85%, respectively, while for epirubicin, median RDI was 95%.
Cycles were delayed for more than 3 days in 27 patients (55%) and
for 45 cycles (21%). Administrations of oral vinorelbine on day 8
were delayed to day 15 for seven patients (14%) and for 10 cycles
(4%) and cancelled for 18 patients (37%) and for 38 cycles (15%).
Overall 20 patients had at least one day 8 either delayed or
cancelled, while 29 patients (59%) received all oral administrations
as per protocol. The principal reason for oral vinorelbine dose
delay and cancellation was haematological toxicity.
Efficacy
Among the 49 enrolled patients, 44 were evaluable for efficacy. The
reasons for nonevaluability were major violation of eligibility criteria
for three patients (one without bidimensionally measurable lesion,
one with incomplete assessment of target lesions at baseline and one
with severe ischaemic heart disease), premature discontinuation for
one patient who refused further therapy after having received one
cycle and lack of tumour assessment for the last patient.
A total of 25 responses (two complete and 23 partial) were
reported, yielding an overall response rate of 51% (95% CI: 36–66)
in intent-to-treat analysis (Table 2). Out of the three noneligible
patients, one was assessed as a partial responder, one as no change
and the last one was nonevaluable due to premature study
discontinuation. The proportion of responders was similar in
patients who had received prior anthracycline/anthracenedione
containing adjuvant chemotherapy (eight of 16 patients: 50%) and
in those who had not (17 of 33: 52%) In the 44 evaluable patients,
the overall response rate was 54.5% (95% CI: 39–70). The median
duration of response was 7.7 months (95% CI: 6.9–12.1). The
median durations of progression-free survival and survival were 8
months (95% CI: 6.9–9.8) and 20 months (95% CI: 15.3–25.3),
respectively.
Toxicity
Toxcity is presented in Table 3. As expected from the toxicity
profile of the study drugs, neutropenia was the main dose-limiting
toxicity. Grade 3 and 4 neutropenia was seen in eight (16%) and 24
(49%) patients, respectively. Febrile neutropenia defined as grade 4
Table 1 Patient and tumour characteristics
N (%)
No. of patients 49
Age (years)
Median 55
Range [27–75]
Median disease-free interval (months) 34
Menopausal status
Pre 33 (67)
Post 16 (33)
Estrogen receptors
Positive 27 (55)
Negative 14 (29)
Unknown 8 (16)
Prior therapy
Radiotherapy 32 (65)
Adjuvant chemotherapy 25 (51)
Adjuvant hormonotherapy 13 (27)
Hormonotherapy for MBC 17 (35)
Karnofsky performance status
100% 19 (39)
90–80% 24 (49)
70% 6 (12)
Visceral involvement 42 (86)
No. of organs involved
1 10 (20)
2 21 (43)
X3 18 (37)
Table 2 Overall response rate
Overall
response
ITT patients (n¼49) Evaluable patients (n¼44)
N (%) N (%)
Complete response 2 (4.1) 2 (4.6)
Partial response 23 (46.9) 22 (50.0)
Response rate
(CR+PR)
25 (51.0) 24 (54.5)
No change 17 (34.7) 16 (36.4)
Progressive disease 4 (8.2) 4 (9.1)
Nonevaluable 3 (6.1) — —
ITT¼intent to treat; CR¼complete response; PR¼partial response.
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patients (8%) and neutropenic infection defined as grade X3
infection concomitant with grade X3 neutropenia was seen in six
patients (12%). In all instances, these complications resolved
under antibiotic therapy.
Among the nonhaematological toxicities, gastrointestinal dis-
orders were the most frequently reported. The proportions of
patients who experienced nausea and vomiting were 86 and 59%,
respectively, but only one and three patients complained of grade 3
or 4, respectively. Stomatitis occurred for 63% of patients and was
scored as grade 3 for five patients (10%). Fatigue was also common
(78% of patients).
Neurotoxicity was uncommon with nine patients (18%) having
experienced mild-to-moderate neurosensory disorders and nine
developing constipation, which was assessed as grade 3 in only one
of them. Cardiotoxicity was minimal: one transient episode of
arrhythmia was observed. Alopecia was almost universal (92% of
patients). No toxic death occurred.
Quality of life
In all, 36 patients completed at least one questionnaire at baseline
and during treatment and 22 (45%) of them had completed regular
quality of life assessments along the study until the fifth cycle (only
one patient completed a questionnaire after the sixth and last
administration). Results of the analysis of these two populations
were similar but more meaningful in the second group of patients.
The analysis of the QLQ-C30 questionnaire showed that patients
did not feel a worsening of their global health status (Figure 1).
Mean changes from baseline in functional and symptom scores are
presented in Figures 2 and 3.
Table 3 Toxicity by patient and by cycle NCI/CTC
Adverse events by NCI/CTC
By patient By cycle
Overall incidence
N (%)
Grade 3
N (%)
Grade 4
N (%)
Overall incidence
N (%)
Grade 3
N (%)
Grade 4
N (%)
Neutropenia 43 (87.8) 8 (16.3) 24 (49.0) 130 (50.4) 27 (10.5) 48 (18.6)
Leucopenia 44 (89.8) 15 (30.6) 12 (24.5) 159 (61.6) 44 (17.1) 15 (5.8)
Anaemia 48 (98.0) 5 (10.2) 1 (2.0) 224 (86.8) 7 (2.7) 1 (0.4)
Thrombocytopenia 26 (53.1) 1 (2.0) 2 (4.1) 58 (22.5) 5 (1.9) 2 (0.8)
Infection
Neutropenic inf. 6 (12.2) 6 (12.2) — 6 (2.3) 6 (2.3) —
Inf. without neutropenia 13 (26.5) — — 28 (10.8) — —
Inf. other 1 (2.0) — — 1 (0.4) — —
Catheter inf. 1 (2.0) 1 (2.0) — 1 (0.4) 1 (0.4) —
Gastrointestinal
Nausea 42 (85.7) 1 (2.0) — 124 (47.9) 1 (0.4) —
Vomiting 29 (59.2) 2 (4.1) 1 (2.0) 56 (21.6) 2 (0.8) 1 (0.4)
Diarrhoea 26 (53.1) 1 (2.0) — 53 (20.5) 1 (0.4) —
Dysphagia 11 (22.5) — — 7 (2.7) — —
Anorexia 5 (10.2) — — 83 (32.1) 6 (2.3) —
Stomatitis 31 (63.3) 5 (10.2) — 18 (7.0) 1 (0.4) —
Constipation 9 (18.4) 1 (2.0) — 23 (8.9) 1 (0.4) —
Dyspepsia 9 (18.4) 1 (2.0) — 11 (4.3) — —
Mouth dryness 7 (14.3) — — 124 (47.9) 1 (0.4) —
Dermatology
Alopecia 45 (91.8) — — NA NA NA
Injection site reaction 19 (38.8) 1 (2.0) — 39 (15.1) 1 (0.4) —
Cardiovascular
Phlebitis 1 (2.0) — — 1 (0.4) 1 (0.4) —
Arrhythmia 1 (2.0) 1 (2.0) — 1 (0.4) 1 (0.4) —
Neurological
Dizziness 6 (12.2) — — 9 (3.5) — —
Neurosensory 9 (18.4) — — 21 (8.1) — —
Vertigo 5 (10.2) — — 9 (3.5) — —
Constitutional
Fatigue 38 (77.6) 3 (6.1) — 140 (54.1) 6 (2.3) —
Fever in the absence of neutropenia 7 (14.3) — — 7 (2.7) — —
Pain
Abdominal 10 (20.4) — — 16 (6.2) — —
Arthralgia 6 (12.2) 2 (4.1) — 16 (6.2) 2 (0.8) —
Headache 9 (18.4) 1 (2.0) — 21 (8.1) 1 (0.4) —
Myalgia 8 (16.3) — — 19 (7.3) — —
Pain other 6 (12.2) — — 13 (5.0) — —
NA¼not applicable. NCI/CTC ¼National Cancer Institute/Common Toxicity Criteria. In all, 258 cycles were evaluable for haematological toxicity. In all, 259 cycles were
evaluable for nonhaematological toxicity.
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emotional score improved. Regarding symptom scores, an
improvement of appetite, pain and sleep was observed, while
fatigue worsened.
The BR23 questionnaire was completed by 21 patients (43%) at
study entry and at all subsequent evaluations. Mean changes in the
scores from baseline are presented in Figures 4 and 5. Body image
and sexual functional scores worsened, but patients became less
worried about their health in the future. Breast and arm symptoms
improved, while systemic therapy score that gathered chemother-
apy side effects worsened.
DISCUSSION
Oral chemotherapy offers significant advantages over i.v. admin-
istration because of its greater convenience for the patient, its ease
of administration and reduced need for hospitalisation. Patients
with incurable cancer showed a clear preference for oral
chemotherapy (Liu et al, 1997; Borner et al, 2002) provided that
its efficacy is similar to the i.v. alternative. However, physicians
have been reluctant to use oral cytotoxic drugs, in the past, because
of important interpatient variations in drug disposition. With the
new generation of oral cytotoxic drugs including oral fluoropyr-
imidines (De Mario et al, 1998) and oral vinorelbine (Marty et al,
2001), reliable blood exposure has been achieved. Therefore, these
new drugs are now progressively replacing their i.v. counterpart.
In the palliative treatment of metastatic breast cancer, oral
vinorelbine used as a single agent was shown to be an effective and
well-tolerated treatment (Freyer et al 2003; Trillet-Lenoir et al,
2004). The next logical step has been to test oral vinorelbine in
combination chemotherapy regimens, which have been shown to
be efficient with i.v. vinorelbine.
For combination regimens, which contain a cytotoxic that is not
orally available, a regimen using i.v. vinorelbine on the day the
other cytotoxic is infused and oral vinorelbine for the rest of the
cycle was investigated in an effort to improve patient convenience.
Clinical experience on the combination of i.v. vinorelbine and
epirubicin in the first-line treatment of MBC is rather extensive
based on several phase II studies (Chadjaa et al, 1993; Ezzat et al,
1996; Baldini et al, 1998; Tabiadon et al, 1998; Nistico et al 1999;
Vici et al, 2002) and a phase III study conducted by the Danish
Breast Cancer Group (DBCG) (Ejlertsen et al, 2001).
In phase II studies, i.v. vinorelbine was generally given at
25mgm
 2 on days 1 and 8 (Chadjaa et al, 1993; Ezzat et al, 1996;
Baldini et al, 1998; Tabiadon et al, 1998) or on days 1 and 5 (Vici
et al, 2002) of every 3-week cycles. Epirubicin was combined on
day 1 of cycles at doses ranging from 60 to 100mgm
 2.
Vici et al chose to administer epirubicin 100mgm
 2 and i.v.
vinorelbine on days 1 and 5 with G-CSF growth factor support
every 3 weeks. Nitisco et al explored a dose-dense regimen where
i.v. vinorelbine 25mgm
 2 and epirubicin 25mgm
 2 were infused
weekly with growth factor support. Response rates ranged from 50
to 77%, the highest rate being achieved with the weekly dose-dense
regimen.
The largest experience has come from the phase III study, which
enrolled a total of 387 patients including 193 treated with i.v.
vinorelbine 25mgm
 2 on days 1 and 8 and epirubicin 90mgm
 2
on day 1 every 3 weeks (Ejlertsen et al, 2004). This combination
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Figure 1 Mean differences of scores with baseline of the 22 patients
who completed all QLQ-C30 questionnaires – global health status.
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Figure 2 Mean differences of scores with baseline of the 21 patients who competed all QLQ-C30 questionnaires – functional scores.
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analysis and 55% in the 175 evaluable patients. Median durations
of progression-free survival and overall survival were 10.1 and 19.1
months, respectively. The most important adverse event was
leucopenia, which was severe in 50% of patients. It was associated
with fever in 20% of patients or severe infection in 11%. Stomatitis
was frequent but severe in only 15% of patients. The incidences of
peripheral neuropathy were 39%, but grade 3 or 4 events were rare.
Only 5% of patients experienced grade 3 or 4 constipation. The
addition of vinorelbine to epirubicin did not increase the risk of
cardiotoxicity.
In the present study, a response rate of 51% was achieved in the
intent-to-treat population and of 54.5% in the 44 evaluable
patients. These results are consistent with prior experience
obtained with a fully i.v. regimen. Similarly, median progres-
sion-free survival of 8 months and median overall survival of 20
months fall in the range expected from the results of the DBCG
study.
As previously reported in the DBCG study, the main toxicities
encountered in this phase II study included neutropenia
and related events as febrile neutropenia (8% of patients) and
neutropenic infection (12%), nausea/vomiting, stomatitis and
fatigue. Neurotoxicity was uncommon and cardiotoxicity was
minimal. No fatal event occurred during the study. This safety
profile is consistent with the tolerance of the fully i.v. regimen.
The day 8 dosing of oral VRL was administered at hospital to
check results of blood cells counts and ensure patient’s
compliance. Oral VRL administered at hospital already offers
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Figure 4 Mean differences of scores with baseline of the 21 patients who competed all QLQ-BR23 questionnaires – functional scores.
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sbenefit to the patient as it decreases the time spent in the hospital
and the incidence of local reaction or stress related to
chemotherapy infusion. Benefit is also for the chemotherapy unit
as oral VRL on day 8 reduces nursing time and costs.
In clinical practice, patient comfort would also be improved by
day 8 oral administration at home provided that hospital team is
trained to manage such patients by phone call and relationship
with the general practioner.
In conclusion, this study indicated that partial substitution of
i.v. vinorelbine by its oral form in combination with epirubicin
seems as effective as the regimen using exclusively i.v. vinorelbine.
In the future, home chemotherapy could be an effective and safe
alternative to outpatient treatment, especially if a fully oral
regimen combining oral vinorelbine with another orally available
cytotoxic agent is developed.
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